LONDON, April 22, 2021 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved JEMPERLI (dostarlimab-gxly), a programmed death ...
As GSK races to match its PD-1 blocking antibody Jemperli to Merck’s superstar Keytruda, new pivotal data could help it expand into a broader endometrial cancer population. Jemperli, used on top of ...
JEMPERLI is indicated as a monotherapy for treatment of adult patients with recurrent or advanced dMMR/MSI-H endometrial cancer, who have progressed on, or are being dosed following, prior treatment ...
Jemperli plus chemotherapy demonstrated improvement in overall survival compared with Keytruda and chemotherapy in patients with treatment-naïve, nonsquamous non–small cell lung cancer. Patients with ...
GSK’s immuno-oncology drug Jemperli has shown intriguing results in a subset of cancer patients with so-called DNA mismatch repair. The British pharma giant has continued to capitalize on that promise ...
After a quick FDA approval in a subgroup of endometrial cancer patients, GSK is trumpeting a win for its Jemperli that might help the PD-1 inhibitor expand to a broader population. Adding Jemperli to ...
The Food and Drug Administration approved Jemperli with carboplatin and paclitaxel for primary advanced or recurrent endometrial cancer. The Food and Drug Administration has approved Jemperli ...
On Monday, the European Commission approved GSK plc’s (NYSE:GSK) Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult patients with ...
Conversion from accelerated to regular (full) approval based on long-term outcomes from the GARNET phase I trial, which demonstrated an overall response rate of 45.4% 85.9% of patients had duration of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results